Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Chemotherapy is Indicated, Yet Used Infrequently, in Patients With MIBC

March 3rd 2014

A review by AndrÃ© P. Fay, MD, on the data supporting the standard use of neoadjuvant and adjuvant chemotherapy for patients with muscle invasive bladder cancers.

Dr. McDermott on Targeting PD-1/PD-L1 in Kidney Cancer

February 28th 2014

David F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses the potential of targeting PD-1 or PD-L1 in patients with kidney cancer

Some With Micropapillary Urothelial Carcinoma May Benefit From HER2-Targeted Treatment

February 27th 2014

Some patients with micropapillary urothelial carcinoma face a three-fold risk of cancer death because their disease amplifies HER2 and overexpresses its protein product, and there may be a role for treatment of the condition with HER2- targeted agent trastuzumab, which has vastly increased the odds of survival for eligible patients with breast cancer.

At Issue: IMRT Self-Referral

February 14th 2014

A study published in the New England Journal of Medicine sparked controversy and criticism when it claimed that many men received unnecessary radiation therapy for their prostate cancer due to self-referral.

Dr. Rini on Barriers to Optimal Care of RCC

February 14th 2014

Brian Rini, MD, associate professor, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, discusses professional practice gaps and barriers to optimal care of renal cell carcinoma (RCC).

Built for the Long Haul: Michigan Institute of Urology Offers Reliable Care in Turbulent Times

February 13th 2014

An inside look at how the Michigan Institute of Urology is navigating the shifting healthcare and civic landscape.

Dr. Tannir on Sunitinib Plus Temsirolimus for mRCC

February 12th 2014

Nizar M. Tannir, MD, FACP, from The University of Texas MD Anderson Cancer Center, discusses a phase I trial of sunitinib and temsirolimus in patients with metastatic renal cell carcinoma.

Dr. Balar on Bevacizumab in Bladder Cancer

February 4th 2014

Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses two trials that evaluate the efficacy of bevacizumab in bladder cancer.

PD-L1 Expression Independent Prognostic Indicator in mRCC

February 3rd 2014

High tumor expression of the protein PD-L1 is independently associated with shorter OS in patients with mRCC receiving treatment with VEGF-targeted therapy.

New Combinations Show Activity in Advanced Urothelial Cancer

February 1st 2014

Two new combinations demonstrated activity in refractory or advanced, previously untreated urothelial carcinoma in phase II evaluations.

Dr. Figlin Describes the Efficacy of AGS-003 in mRCC

February 1st 2014

Robert Figlin, MD, FACP, discusses updated data on the ADAPT trial, which is an ongoing international phase III randomized trial of autologous dendritic cell immunotherapy (AGS-003) plus standard treatment in metastatic renal cell carcinoma (mRCC)

Survival Remains Unchanged in Metastatic Urothelial Cancer Despite Increasing Use of Second-Line Therapies

February 1st 2014

Survival, measured as either disease-specific survival or relative conditional survival, has not improved for patients with metastatic urothelial carcinoma despite increasing use of second-line therapies with no formal indication in this setting.

Dr. Pal on RCS in Metastatic Urothelial Carcinoma

January 31st 2014

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses changes in relative conditional survival in metastatic urothelial carcinoma.

ASIs Demonstrate OS Benefit in mRCC, Appear Synergistic with Anti-VEGF Therapies

January 28th 2014

A vast, pooled retrospective analysis has demonstrated that the use of ASIs may significantly improve survival outcomes in patients with mRCC.

TKI Treatment Choices in mRCC Often Hinge on Dosing, Toxicities

January 27th 2014

During the past decade, several oral tyrosine kinase inhibitors targeting the vascular endothelial growth factor have been approved for the first-line treatment of metastatic renal cell carcinoma.

Five Ways the ACA Will Affect Urology Practices: Insights from a health policy expert

January 24th 2014

Organization into large group practices will be a key way for urologists to successfully navigate a healthcare system that continues to be fraught with an enormous amount of change, a keynote speaker said during LUGPA's annual meeting in Chicago in November.

Dr. Kapoor on LUGPA's Successes and Challenges

January 22nd 2014

Deepak A. Kapoor, MD, former president of the Large Urology Group Practice Association (LUGPA), discusses the successes of and challenges facing LUGPA.

The History of Integrated Practice

January 21st 2014

We enjoyed record attendance this year by both physicians and administrators, and despite the pressures of groups being purchased by integrated hospital systems, the organization continues to grow.

Low Serum Albumin Before Surgery is Predictor of Complications Following Radical Cystectomy

January 15th 2014

Poor nutritional status-specifically, a low level of serum albumin-is a predictor of complications following radical cystectomy for patients with bladder cancer

Urologists Encouraged to Embrace Risk-Based Budgeting

January 14th 2014

As fee-for-service models dwindle under healthcare reform, new reimbursement models based on risk are emerging.